Deep Tech Startups

OTI Lumionics develops advanced materials for electronics, focused on key enabling materials for OLED displays used in next-generation consumer electronics and automotive, including electrode materials and self-assembly patterning technology. It uses a computational Materials Discovery Platform combining quantum simulations and machine learning with in-house pilot production testing, and works with Tier 1 chemical partners for scale-up.

5 investors

Overview AI builds AI-powered vision systems that detect manufacturing defects in real-time across production lines, learning and adapting to any product within hours. The system serves manufacturers across automotive, pharmaceutical, and other high-volume production industries globally.

5 investors

PanTera develops actinium-225, a therapeutic radioisotope used in precision cancer treatment through radiotheranostics, serving oncology patients and pharmaceutical companies globally. The company operates a production facility in Belgium producing high-purity actinium-225 as an active pharmaceutical ingredient for personalized nuclear medicine treatments.

5 investors

Parallel Wireless develops open radio access network (RAN) software and solutions for telecommunications operators. The company provides cost-effective, resilient LTE and 5G network architecture for wireless communications.

5 investors

Peptone develops a product engine to design small-molecule drug candidates targeting intrinsically disordered proteins, which have been difficult to address with conventional drug discovery approaches.

5 investors

Perseus Proteomics (PPMX) is a Japanese biotech company that uses proprietary antibody technology to develop new antibody-based drugs. It also provides antibody research support services and sells antibodies and reagents, including PTX3 measurement kits.

5 investors

Phantom AI develops a modular, software-based autonomous driving stack, including deep learning computer vision (PhantomVision), sensor fusion (PhantomFusion), and vehicle control (PhantomDrive) for Euro NCAP-compliant ADAS and level 2/3 autonomy. Its main customers are Tier 1 automotive suppliers and OEMs building advanced driver assistance systems.

5 investors

Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.

5 investors

PlasmaLeap builds plasma-based, zero-emissions chemical reactors for the synthesis of green fuels and chemicals and for treating hazardous industrial waste. It serves industrial and academic research customers within the Power-to-X and green chemical production space.

5 investors

Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies. The platform combines machine learning, medicinal chemistry, and software engineering to improve the drug development process.

5 investors

Pow.Bio develops a high-efficiency continuous fermentation platform for biomanufacturing that enables production of biotech products at lower cost and faster timelines. The platform serves bioproduct manufacturers across synthetic biology, food, pharmaceuticals, and specialty chemicals.

5 investors

Pragmatic Semiconductor makes FlexICs, ultra-thin flexible integrated circuits built with thin-film transistor technology on flexible substrates for edge and item-level intelligence applications. The chips have a low carbon footprint and short production cycles measured in days.

5 investors

Precision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts. The company works with hospital clinical partners on implanted studies and positions its technology as removable and upgradable without damaging the brain.

5 investors

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression. The company leverages expertise in mitochondrial biology and drug discovery to create treatments for diseases associated with mitochondrial dysregulation.

5 investors

Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R. Liu's lab at the Broad Institute of MIT and Harvard. The company aims to treat a broad range of genetic diseases.

5 investors

Probius develops Quantum Electrochemical Spectroscopy (QES), a label- and reagent-free electrochemical sensing technology that detects and quantifies thousands of analytes—proteins, metabolites, and cells—from microliter-scale biological samples in about 30 minutes. The platform generates digital representations of biological specimens and cloud-based multiplex assays intended to feed AI models of biology for biomarker discovery, drug development, and bioproduction quality control.

5 investors

Project Omega recycles spent nuclear fuel to rebuild the domestic nuclear fuel cycle, using chemistry processing to remove key isotopes and develop new products for the nuclear economy. It also builds transportable, long-duration nuclear power systems, such as its Zero Day Hybrid Power System, for national security, space, and maritime missions in the United States.

5 investors

Prolific Machines licenses an optogenetics platform that adds light-based control to cell line development and GMP biomanufacturing, letting biopharma teams retrofit existing bioreactors and hosts to raise titers and manufacture complex molecule formats. It targets biopharmaceutical developers and manufacturers seeking higher productivity on difficult programs without re-platforming.

5 investors

Proteinea uses proprietary AI models and computational tools to engineer antibodies, focusing on rational design of antibody Fc domains for improved efficacy, half-life, and targeted biodistribution. It combines AI-driven design frameworks with wet-lab validation to develop Fc-optimized antibody scaffolds for therapeutic development.

5 investors

Pyper Vision develops fog-casting technology that forecasts fog over airports, aimed at reducing fog-related flight delays and disruptions in the aviation sector. The company's longer-term goal is fog dispersal to fully resolve fog-related disruptions.

5 investors

Quantum Art designs and builds scalable quantum computers aimed at commercial applications across various industries. The company focuses on developing quantum computing solutions for commercial use at scale.

5 investors

Quidnet Energy develops geomechanical energy storage technology that repurposes existing oil, gas, and hydroelectric infrastructure to provide grid-scale, long-duration energy storage. The company serves utilities and grid operators seeking scalable solutions for the energy transition.

5 investors

Quintessent develops optical connectivity solutions to address chip-to-chip communication bottlenecks in large-scale computing and AI systems. The company's technology aims to enable faster inter-chip communication as a critical infrastructure component for scaling compute performance.

5 investors

Reditus Space builds reusable spacecraft systems that enable routine return of cargo from low Earth orbit, supporting in-space manufacturing and physical industrialization of space. The company provides infrastructure for commercial operators and manufacturers to deliver products and materials back to Earth economically.

5 investors